Trial Profile
Phase III trial of birch-pollen allergy immunotherapy (AllerT) for the treatment of birch pollen allergies
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2015
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy-Anergis (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- 17 Apr 2015 New trial record
- 01 Apr 2015 According to an Anergis media release, the dose regimen for this trial will be selected on the basis of the results of phase II trial of AllerT (see profile 700250587).